MX346879B - Ready to use ketorolac formulations. - Google Patents

Ready to use ketorolac formulations.

Info

Publication number
MX346879B
MX346879B MX2013004393A MX2013004393A MX346879B MX 346879 B MX346879 B MX 346879B MX 2013004393 A MX2013004393 A MX 2013004393A MX 2013004393 A MX2013004393 A MX 2013004393A MX 346879 B MX346879 B MX 346879B
Authority
MX
Mexico
Prior art keywords
ready
ketorolac formulations
pharmaceutically acceptable
use ketorolac
formulations
Prior art date
Application number
MX2013004393A
Other languages
Spanish (es)
Other versions
MX2013004393A (en
Inventor
Joseph Pergolizzi
Alexander Mironov
Chad James Pickens
Douglas Giles Johnson
Original Assignee
Rtu Pharmaceuticals Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rtu Pharmaceuticals Llc filed Critical Rtu Pharmaceuticals Llc
Publication of MX2013004393A publication Critical patent/MX2013004393A/en
Publication of MX346879B publication Critical patent/MX346879B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Disclosed in certain embodiments is a pharmaceutical composition for parenteral administration comprising: an aqueous solution comprising ketorolac or a pharmaceutically acceptable salt thereof in an amount from about 0.1 mg/mL to about 10 mg/mL; and a pharmaceutically acceptable excipient; wherein the formulation is substantially free of alcohol.
MX2013004393A 2010-10-21 2011-10-21 Ready to use ketorolac formulations. MX346879B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US40538410P 2010-10-21 2010-10-21
US201161481602P 2011-05-02 2011-05-02
PCT/US2011/057284 WO2012054831A2 (en) 2010-10-21 2011-10-21 Ready to use ketorolac formulations

Publications (2)

Publication Number Publication Date
MX2013004393A MX2013004393A (en) 2014-09-12
MX346879B true MX346879B (en) 2017-04-03

Family

ID=45973506

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013004393A MX346879B (en) 2010-10-21 2011-10-21 Ready to use ketorolac formulations.

Country Status (18)

Country Link
US (5) US9421191B2 (en)
EP (3) EP4190327A1 (en)
JP (1) JP6013346B2 (en)
KR (4) KR102307601B1 (en)
CN (2) CN108703948A (en)
CA (1) CA2814805C (en)
CY (1) CY1122516T1 (en)
DK (1) DK2616064T3 (en)
ES (2) ES2933198T3 (en)
HR (1) HRP20191994T1 (en)
HU (1) HUE045889T2 (en)
LT (1) LT2616064T (en)
MX (1) MX346879B (en)
PL (1) PL2616064T3 (en)
PT (1) PT2616064T (en)
RS (1) RS59526B1 (en)
SI (1) SI2616064T1 (en)
WO (1) WO2012054831A2 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2616064T3 (en) 2010-10-21 2019-11-11 Rtu Pharmaceuticals Llc KETOROLAC FORMULATIONS READY TO USE
US10098872B1 (en) 2013-07-22 2018-10-16 William Bradley Worthington Analgesic formulations and methods for reduced postoperative nausea and vomiting and enhanced postoperative pain relief
US11992484B2 (en) 2013-07-22 2024-05-28 Hutchison Health, Llc Analgesic formulations and methods for reduced postoperative nausea and vomiting and enhanced postoperative pain relief
US11559521B2 (en) * 2013-07-22 2023-01-24 William Bradley Worthington Analgesic formulations and methods for reduced postoperative nausea and vomiting and enhanced postoperative pain relief
US11992485B2 (en) 2013-07-22 2024-05-28 Hutchison Health, Llc Analgesic formulations and methods for reduced postoperative nausea and vomiting and enhanced postoperative pain relief
CA3042642A1 (en) 2013-08-12 2015-02-19 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
WO2015095391A1 (en) 2013-12-17 2015-06-25 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
CN103830171B (en) * 2014-03-04 2015-11-18 鲁南制药集团股份有限公司 A kind of Ketorolac tromethamine injection and preparation method thereof
CA2955229C (en) 2014-07-17 2020-03-10 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
EP3209282A4 (en) 2014-10-20 2018-05-23 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
LT3256138T (en) * 2015-11-25 2022-06-10 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
IT201600075246A1 (en) * 2016-07-19 2018-01-19 Jointherapeutics S R L Compositions comprising a polysaccharide matrix for the controlled release of active principles.
EP3621621A4 (en) * 2017-05-10 2021-03-31 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
FR3101917B1 (en) 2019-10-09 2022-07-15 Ifp Energies Now Single radiator cooling system
CN110812325B (en) * 2019-11-13 2022-04-05 鲁南制药集团股份有限公司 Method for improving storage stability of ketorolac tromethamine injection
CN113679676A (en) * 2020-05-19 2021-11-23 南京海融医药科技股份有限公司 Pharmaceutical composition of levoketorolac and preparation method thereof
CN114159384B (en) * 2021-02-07 2023-04-07 南京锐志生物医药有限公司 Low-irritation ketorolac tromethamine injection with stable chemical properties
EP4360622A1 (en) * 2021-06-24 2024-05-01 Shanghai Aurora Biotechnology Co., Ltd. Ketorolac liquid composition, preparation method therefor, and application thereof
CN113384524A (en) * 2021-07-05 2021-09-14 四川尚锐生物医药有限公司 Preparation method of stable ketorolac tromethamine injection
CN114191384A (en) * 2021-12-20 2022-03-18 成都倍特药业股份有限公司 Instant ketorolac tromethamine and etazocine hydrobromide combined liquid preparation
CN114432240A (en) * 2022-03-04 2022-05-06 郑州市中心医院 Stable non-irritating ketorolac tromethamine injection and preparation method thereof

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4089969A (en) 1976-07-14 1978-05-16 Syntex (U.S.A.) Inc. 5-Aroyl-1,2-dihydro-3H-pyrrolo[1,2-a]pyrrole-1-carboxylic acid derivatives and process for the production thereof
US5214052A (en) 1987-07-28 1993-05-25 Mitsubishi Kasei Corporation Method for dissolving arginineamides and pharmaceutical compositions containing them
DE69824277T2 (en) 1997-07-11 2004-09-23 Toray Industries, Inc. STABLE MEDICAL COMPOSITIONS CONTAINING 4,5-EPOXYMORPHINE DERIVATIVES
US6608073B1 (en) 1998-10-14 2003-08-19 New Millennium Pharmaceutical Research, Inc. Intranasal codeine for the rapid suppression of cough and rapid relief of pain
PT1165044E (en) 1999-03-26 2004-10-29 Pozen Inc HIGH POWER DI-HYDRO-PYROTAMINE COMPOUNDS
US20040022787A1 (en) * 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
US6509027B2 (en) * 2001-02-12 2003-01-21 Supergen, Inc. Injectable pharmaceutical composition comprising coated particles of camptothecin
US20030191187A1 (en) * 2002-04-01 2003-10-09 Lee Fang Yu Injectable pharmaceutical composition containing a non-steroidal anti-inflammatory drug and method for preparing the same
US20040105881A1 (en) * 2002-10-11 2004-06-03 Gregor Cevc Aggregates with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin
PL2368553T3 (en) 2003-04-08 2015-05-29 Progenics Pharm Inc Pharmaceutical formulations containing methylnaltrexone
US20070049552A1 (en) 2003-04-14 2007-03-01 Babu Manoj M Fluoroquinolone formulations and methods of making and using the same
US20080317681A1 (en) * 2003-07-11 2008-12-25 Petros Gebreselassie Compositions containing a stain removing complex, and methods of making and using the same
US20050266031A1 (en) 2004-05-25 2005-12-01 Jay Dickerson Pharmaceutical suspension composition
CN101039699B (en) * 2004-10-15 2011-07-27 柳署弘 Methods and compositions for reducing toxicity of a pharmaceutical compound
US8148356B2 (en) 2005-08-24 2012-04-03 Cumberland Pharmaceuticals, Inc. Acetylcysteine composition and uses therefor
RU2416393C2 (en) 2005-09-01 2011-04-20 Бакстер Интернэшнл Инк. Preparative form of argatroban
US20070142478A1 (en) 2005-12-21 2007-06-21 Erning Xia Combination antimicrobial composition and method of use
US8492400B2 (en) 2006-02-09 2013-07-23 Santen Pharmaceutical Co., Ltd. Stable formulations, and methods of their preparation and use
DOP2007000055A (en) * 2006-04-10 2007-10-31 Senosiain S A De C V Lab PHARMACEUTICAL COMPOSITION INCLUDING AN ANALGESIC AND VITAMINS
BRPI0709617A2 (en) 2006-04-18 2011-07-19 Ekr Therapeutics Inc pharmaceutical composition, and, methods to treat acute elevations of blood pressure in a human subject, to induce hypotension in a human subject, and to produce a pharmaceutical composition for intravenous administration
WO2007146795A2 (en) 2006-06-12 2007-12-21 Ironwood Pharmaceuticals, Inc. Pharmaceutical formulation for parenteral administration
KR20090024282A (en) * 2006-06-29 2009-03-06 쉐링 코포레이션 Sugar-free storage-stable antihistaminic syrups
US20080014274A1 (en) 2006-07-14 2008-01-17 Wyeth Enhanced stability phenylephrine liquid compositions
TWI489984B (en) 2006-08-04 2015-07-01 Wyeth Corp Formulations for parenteral delivery of compounds and uses thereof
US20080057023A1 (en) 2006-08-29 2008-03-06 Chynn Emil W Oxygenated ophthalmic composition
WO2008039473A2 (en) 2006-09-27 2008-04-03 Scidose Llc Alcohol free formulation of argatroban
KR100836624B1 (en) 2006-12-08 2008-06-10 한국전자통신연구원 Device of variable fast furier transform and method thereof
US20080312154A1 (en) * 2007-06-15 2008-12-18 Barbara Lee Peterlin Administration of adipocytokine and adiponectin for treating headache and methods of diagnosing headache by measuring adiponectin
MX2010002409A (en) 2007-09-03 2010-05-19 Nanotherapeutics Inc Particulate compositions for delivery of poorly soluble drugs.
WO2009087658A2 (en) * 2007-11-07 2009-07-16 Sun Pharma Advanced Research Company Limited Composition suitable for parenteral administration
US9399012B2 (en) 2007-11-13 2016-07-26 Mallinckrodt Ip Reduced dose intravenous acetaminophen
US20090239836A1 (en) * 2008-03-24 2009-09-24 Mary Lee Ciolkowski Multifunctional Ophthalmic Compositions
US8956636B2 (en) 2008-04-18 2015-02-17 Warsaw Orthopedic, Inc. Methods and compositions for treating postoperative pain comprosing ketorolac
US7635773B2 (en) * 2008-04-28 2009-12-22 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions
TWI397038B (en) * 2008-11-05 2013-05-21 Au Optronics Corp Display panel using a half source driver structure and display data supplying method thereof
CN103108637B (en) * 2010-07-19 2018-09-14 比根切萨彼公司 The intravenous method for applying glibenclamide and other drugs
MY173215A (en) 2010-07-21 2020-01-06 Cumberland Pharmaceuticals Inc Acetylcysteine compositions and methods of use thereof
DK2616064T3 (en) 2010-10-21 2019-11-11 Rtu Pharmaceuticals Llc KETOROLAC FORMULATIONS READY TO USE

Also Published As

Publication number Publication date
PL2616064T3 (en) 2020-02-28
CN108703948A (en) 2018-10-26
MX2013004393A (en) 2014-09-12
ES2753981T3 (en) 2020-04-15
JP6013346B2 (en) 2016-10-25
US20190105301A1 (en) 2019-04-11
US20220023260A1 (en) 2022-01-27
DK2616064T3 (en) 2019-11-11
KR102307601B1 (en) 2021-09-30
CA2814805A1 (en) 2012-04-26
US20180280351A1 (en) 2018-10-04
EP4190327A1 (en) 2023-06-07
KR20140012029A (en) 2014-01-29
PT2616064T (en) 2019-11-06
US9962371B2 (en) 2018-05-08
EP2616064B1 (en) 2019-08-07
KR20180119610A (en) 2018-11-02
WO2012054831A3 (en) 2012-06-07
US11116750B2 (en) 2021-09-14
CN103167800A (en) 2013-06-19
EP3632432A1 (en) 2020-04-08
EP2616064A2 (en) 2013-07-24
JP2013543843A (en) 2013-12-09
US9421191B2 (en) 2016-08-23
US20120101142A1 (en) 2012-04-26
EP2616064A4 (en) 2016-07-20
RS59526B1 (en) 2019-12-31
US20170007575A1 (en) 2017-01-12
HUE045889T2 (en) 2020-01-28
SI2616064T1 (en) 2019-12-31
KR20200078541A (en) 2020-07-01
WO2012054831A2 (en) 2012-04-26
LT2616064T (en) 2019-11-25
CA2814805C (en) 2021-11-02
KR20190085561A (en) 2019-07-18
HRP20191994T1 (en) 2020-02-07
CY1122516T1 (en) 2021-01-27
KR102114568B1 (en) 2020-05-22
US10278959B2 (en) 2019-05-07
EP3632432B1 (en) 2022-09-14
ES2933198T3 (en) 2023-02-02

Similar Documents

Publication Publication Date Title
MX346879B (en) Ready to use ketorolac formulations.
NZ599847A (en) Pharmaceutical composition comprising a glp-1 agonist and methionine
WO2013101897A3 (en) Improved compositions and methods for delivery of omeprazole plus acetylsalicylic acid
NZ605887A (en) Pharmaceutical dosage form comprising 6’-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4’,9’-dihydro-3’h-spiro[cyclohexane-1,1’-pyrano[3,4,b]indol]-4-amine for the treatment of neuropathic pain
MX351584B (en) Aqueous pharmaceutical formulation of tapentadol for oral administration.
ECSP088974A (en) IMIDAZOL PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF DISEASES RELATED TO THE SYNTHEOSE QUINASA GLYCOGEN (GSK3)
UA106636C2 (en) MORPHOLINOTIAZOLES AS A POSITIVE ALLOSTERIC ALPHA MODULATORS 7
WO2012035559A3 (en) Sustained release pharmaceutical compositions comprising pregabalin
MX2010014234A (en) Pyrazole compounds 436.
MX2014001101A (en) 17-hydroxyprogesterone ester-containing oral compositions and related methods.
IL218165A (en) Highly concentrated stable pharmaceutical formulations for subcutaneous administration of a pharmaceutically active anti-cd20 antibody
NZ595467A (en) Sublingual pharmaceutical composition comprising a neutral oil
WO2012079092A3 (en) Testosterone undecanoate compositions
MD20150050A2 (en) Stable preservative-free mydriatic and anti-inflammatory solutions for injection
MX2012003082A (en) Pharmaceutical compositions for reducing alcohol-induced dose dumping.
RS54438B1 (en) Pharmaceutical dosage form comprising 6'-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine
WO2009066152A3 (en) Haloallylamine inhibitors of ssao/vap-1 and uses therefor
AR075735A1 (en) PHARMACEUTICAL COMPOSITIONS OF IMMEDIATE RELEASE THAT INCLUDE OXYCODONE AND NALOXONE. USE
EA201170527A1 (en) PHARMACEUTICAL COMPOSITIONS, INCLUDING BORONIC ACID COMPOUNDS
NZ753904A (en) Compositions and methods for treating anemia
NZ606123A (en) Use of binders for manufacturing storage stable formulations
NZ595767A (en) Composition for the treatment of prostate cancer
NZ703564A (en) Oral formulations and lipophilic salts of methylnaltrexone
WO2014027975A3 (en) Novel orally administered pharmaceutical formulations
WO2012007159A3 (en) Novel gastro-retentive dosage forms

Legal Events

Date Code Title Description
FG Grant or registration